Immunovant, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
IMVT
Immunovant, INCRoivant Sciences Ltd. increased its beneficial ownership in Immunovant, Inc. to 55.9% by acquiring 16.67 million shares in a recent public offering.
NASDAQ
IMVT
Immunovant, INCSCHEDULE 13D/A: Immunovant Appoints Roivant Executive Eric Venker as New CEO in Latest Schedule 13D/A Amendment
Immunovant, Inc. announced the appointment of Eric Venker, M.D., President and Chief Operating Officer of Roivant Sciences, Inc., as its new Chief Executive Officer, effective April 21, 2025, as detailed in an amended Schedule 13D filing by major shareholder Roivant Sciences Ltd.
NASDAQ
IMVT
Immunovant, INCSCHEDULE 13D/A: Roivant Sciences Boosts Immunovant Stake with $337 Million Private Placement for Pipeline Advancement
Roivant Sciences Ltd. has increased its beneficial ownership in Immunovant, Inc. to 56.9% through a $337 million private placement, providing capital for Immunovant's development pipeline and general corporate purposes.